Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03880656 · ClinicalTrials.gov registry record · Phase 1
BM-MNCs for Lower Extremity Compartment Syndrome Injury
A Phase 1 study of Compartment Syndrome Traumatic Lower Extremity, sponsored by Oregon Health and Science University.
- Active
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT03880656 is a Phase 1 study of Compartment Syndrome Traumatic Lower Extremity that is active but no longer recruiting, run by Oregon Health and Science University. The registered enrollment target is 18 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03880656, a Phase 1 study of Compartment Syndrome Traumatic Lower Extremity, is active but no longer recruiting, sponsored by Oregon Health and Science University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 1 study to assess safety and tolerability of intramuscular administration of two different doses of autologous bone marrow mononuclear cells (BM-MNCs) for treatment of lower extremity injury complicated by compartment syndrome injury.
Conditions Studied
Interventions
- BIOLOGICAL Intramuscular administration of autologous BM-MNCs
Study Locations (1)
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-12-04 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03880656
The ClinicalTrials.gov registry entry for NCT03880656 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Compartment Syndrome Traumatic Lower Extremity appearing as the primary indexed condition, and to 1 intervention - of which Intramuscular administration of autologous BM-MNCs is the first listed.
NCT03880656 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT03880656 about?
NCT03880656 is a clinical study titled "BM-MNCs for Lower Extremity Compartment Syndrome Injury". This is a phase 1 study to assess safety and tolerability of intramuscular administration of two different doses of autologous bone marrow mononuclear cells (BM-MNCs) for treatment of lower extremity injury complicated by compartment syndrome injury.
What is the current status of trial NCT03880656?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2019-12-04. Estimated completion is 2026-06.
What conditions does trial NCT03880656 study?
This clinical trial studies the following conditions: Compartment Syndrome Traumatic Lower Extremity.
What interventions are being tested in trial NCT03880656?
The interventions under investigation include: Intramuscular administration of autologous BM-MNCs (BIOLOGICAL).
Who is sponsoring clinical trial NCT03880656?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03880656 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.